Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 1, 2003, Pages 93-97

  Aumais, G ^a,b   Lefebvre, M ^a   Tremblay, C ^a   Bitton, A ^c   Martin, F ^d   Giard, A ^f   Madi, M ^a   Spenard J ^e  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

^d Clin de Gastro Enterologie du C V   (Canada)

^e Axcan Pharma Inc   (Canada)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROCTITIS; RECTUM BIOPSY; SINGLE DRUG DOSE; STEADY STATE; SUPPOSITORY; ULCERATIVE COLITIS; VOLUNTEER;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; COLITIS, ULCERATIVE; FEMALE; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; MESALAMINE; MIDDLE AGED; RECTUM; SUPPOSITORIES;

EID: 0037247819     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01409.x     Document Type: Article

References (12)

1. William CN, Haber G, Aquino JA. Double-blind, placebo-controlled evaluation of 5-ASA suppositories in active distal proctitis and measurement of extent of spread using 99mTc-labeled 5-ASA suppositories. Dig Dis Sci, 1987; 32(1.2 Suppl.): 71S-75S.
2. Ngo Y, Rambaud JC. 5-aminosalicylic acid enema (Pentasa) versus hydrocortisone acetate foam (Proctocort) for the treatment of outbreaks of proctitis and cryptogenetic proctosigmoiditis. A comparative randomized multicenter trial. Gastroenterol Clin Biol 1992: 16(6-7): 558-63.
3. Ngo Y, Gelinet JM, Ivanovic A, et al. Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial. Gastroenterol Clin Biol 1992; 16(10): 782-6.
4. Farup PG. Horde O. Halvorsen FA. Raknerud N. Brodin U. Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. Scand J Gastroenterol 1995; 30(2): 164-70.
5. Hanauer S, Good L, Goodman MW, et al. Long-term use of mesalazine suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 2000; 95(7): 1749-54.
6. Brown J, Haines S. Wilding IR. Colonic spread of three rectally administered mesalazine (Pentasa) dosage forms in healthy volunteers as assessed by gamma scintigraphy. Aliment Pharmacol Ther 1997; 11(4): 685-91.
7. Frieri G, Giacomelli R. Pimpo M. et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 2000; 47(3): 410-4.
8. Naganuma M, Iwao Y. Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalazine and sulfasalazine. Inflamm Bowel Dis 2001; 7(3): 221-5.
9. Hussain FN. Ajjan RA, Riley SA. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol 2000; 49(4): 323-30.
10. Hussain FN, Ajjan RA, Kapur K, Moustafa M. Riley SA. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15(1): 53-62.
11. Frieri G, Pimpo MT, Palumbo G, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999; 13(11): 1413-7.
12. Gionchetti P, Rizzello F. Venturi A. et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41(1): 93-7.